FDA grants accelerated approval to dostarlimab for a defined rectal-cancer group — history

Revision 1 — October 20, 2026

Initial source-attributed record prepared October 20, 2026. No earlier Iliyn revision or correction exists for this record.

For factual corrections, use the contact information on Privacy and contact.

Current report